NCT04545762View on ClinicalTrials.gov

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Refractory Non-Hodgkin LymphomaBurkitt LymphomaMantle Cell LymphomaFollicular LymphomaLymphoplasmacytic LymphomaPrimary Mediastinal Large B Cell LymphomaDiffuse Large B Cell LymphomaSmall Lymphocytic LymphomaTransformed LymphomaNon-Hodgkin Lymphoma
Interventions
DRUG

Fludarabine

Given intravenously (IV)

DRUG

Cyclophosphamide

Given intravenously (IV)

BIOLOGICAL

anti-CD19 CAR-T cells

Single infusion

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

University of California, Davis

OTHER

lead

C. Babis Andreadis

OTHER

NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter